Journal of Intensive Medicine创刊号正式上线!

2021-08-16 网络 网络

Journal of Intensive Medicine

Journal of Intensive Medicine是由中华医学会主办,中华医学会杂志社出版发行的重症医学领域英文新刊。入选2020年“中国科技期刊卓越行动计划”高起点新刊项目,由中华医学会重症医学分会候任主任委员、上海交通大学医学院附属瑞金医院重症医学科主任陈德昌教授担任主编,欧洲重症医学会(ESICM)心脏动力学分会主席Jean-Louis Teboul教授担任共同主编。新刊编委会由国内外重症医学领域的56位权威专家组成,同时还组建了一只由国内47位学术活跃的重症医学专家组成通讯编委队伍。

 

图片

Journal of Intensive Medicine 主要发表原创性论文及综述。新刊重点报道国内外重症医学及相关领域的最新研究进展,追踪国内外学术前沿、促进国内外学术交流,引领创新,深化基础研究,提升临床理论与实践结合、临床与基础结合。为重症医学及相关领域的医护人员、临床和基础研究者提供展示研究工作成果、答疑解惑、交流思想、扩大影响的广阔平台。Journal of Intensive Medicine同爱思唯尔(Elsevier)合作,利用ScienceDirect出版平台进行展示,有较好的展示度和传播度。

打开期刊论坛:Journal of Intensive Mediciney论坛

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2039271, encodeId=abee20392e156, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Sep 06 03:16:52 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859183, encodeId=54841859183d4, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Jun 24 00:16:52 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773987, encodeId=da271e7398735, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Nov 25 17:16:52 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577834, encodeId=112115e7834dc, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Aug 18 08:16:52 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611225, encodeId=378116112255d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 18 08:16:52 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2039271, encodeId=abee20392e156, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Sep 06 03:16:52 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859183, encodeId=54841859183d4, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Jun 24 00:16:52 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773987, encodeId=da271e7398735, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Nov 25 17:16:52 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577834, encodeId=112115e7834dc, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Aug 18 08:16:52 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611225, encodeId=378116112255d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 18 08:16:52 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
    2022-06-24 jeanqiuqiu
  3. [GetPortalCommentsPageByObjectIdResponse(id=2039271, encodeId=abee20392e156, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Sep 06 03:16:52 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859183, encodeId=54841859183d4, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Jun 24 00:16:52 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773987, encodeId=da271e7398735, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Nov 25 17:16:52 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577834, encodeId=112115e7834dc, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Aug 18 08:16:52 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611225, encodeId=378116112255d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 18 08:16:52 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
    2021-11-25 kalseyzl
  4. [GetPortalCommentsPageByObjectIdResponse(id=2039271, encodeId=abee20392e156, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Sep 06 03:16:52 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859183, encodeId=54841859183d4, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Jun 24 00:16:52 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773987, encodeId=da271e7398735, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Nov 25 17:16:52 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577834, encodeId=112115e7834dc, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Aug 18 08:16:52 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611225, encodeId=378116112255d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 18 08:16:52 CST 2021, time=2021-08-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2039271, encodeId=abee20392e156, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Sep 06 03:16:52 CST 2021, time=2021-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859183, encodeId=54841859183d4, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Jun 24 00:16:52 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773987, encodeId=da271e7398735, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Nov 25 17:16:52 CST 2021, time=2021-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577834, encodeId=112115e7834dc, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Aug 18 08:16:52 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611225, encodeId=378116112255d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Aug 18 08:16:52 CST 2021, time=2021-08-18, status=1, ipAttribution=)]

相关资讯

肠外营养:永不说永不

这篇综述分析了危重症患者相关适应症下足量适时给予肠外营养(PN)的益处。 危重症患者在ICU住院期间有能量缺乏的风险,这会导致预后不良,缘由继发于应激反应的分解代谢过度和优化饮食困难。因为没有单一精确预测能量消耗的等量指标,直接热量测定推荐用于定义能量指标。能量代谢与蛋白代谢密切相关。近期证据呼吁足量蛋白摄入,然而没有精确的方法来估计蛋白需求量,且推荐大多是次优的。肠内营养(EN)是进食常规

卫健委:十省市1200名重症医学专业医生护士今天将到武汉

2月2日下午15时,国家卫生健康委召开新闻发布会,介绍新型冠状病毒感染的肺炎疫情防控工作中公共场所、交通工具以及不同风险人群的健康防护有关情况。 国家卫生健康委员会新闻发言人米锋在发布会上说,很多媒体也在关注现在救治力量的问题,遏制传播和加强救治是现在疫情防控的重中之重。2月1日,国家卫生健康委再次从全国调派专业力量,保证武汉重症患者得到医疗救治,今天10省市1200名重症医学专业的医生

重症医学:是吃还是呼吸?

危重病人治疗过程中,常常需要优先处理呼吸窘迫的问题。无创通气(NIV)因可以避免气管插管,临床应用也越来越多。NIV治疗过程中,经口进食或胃肠营养支持支持,因存在误吸的风险,被认为是不安全的。所以,这类患者经常存在热量和蛋白摄入不足。新的治疗手段,如高流量鼻吸氧,允许进行更合适的经口进食。

重症医学:什么是ICU的安全镇静

近几十年来,出于对重症监护室(ICU)中接受机械通气患者的舒适性和安全性考虑,深度镇静是必不可少的,因而阿片类药物以及神经肌肉阻滞剂的使用非常广泛。随着ICU资源和支出需求的不断增加,临床上开始研究目前的镇静方案是否真正减轻了患者急性期的不适,减少了随之而来的因危重疾病导致的不愉快的回忆,防止了意外拔管以及导管脱落。

镇痛镇静--从绝望中寻找希望

患者概况 男,51岁,身高175cm,理想体重60kg,2017年6月21日入院,2017年7月2日入ICU。发现左锁骨上淋巴结长大2+年,反复胸闷、气促1+年,加重伴发热1周。

ICU床位数四年增幅达16.4%,重症医学将迎来信息化大发展?

每当遇到重大公共卫生事件时,重症医学科便会引起社会的广泛关注和重视。